- Home
- ELAB vs GRI Comparison
ELAB vs GRI Comparison
Compare ELAB & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- GRI
- Stock Information
- Founded
- ELAB 2020
- GRI 2018
- Country
- ELAB United States
- GRI United States
- Employees
- ELAB N/A
- GRI N/A
- Industry
- ELAB
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- GRI Health Care
- Exchange
- ELAB Nasdaq
- GRI Nasdaq
- Market Cap
- ELAB 3.2M
- GRI 3.6M
- IPO Year
- ELAB 2023
- GRI N/A
- Fundamental
- Price
- ELAB $4.78
- GRI $1.81
- Analyst Decision
- ELAB
- GRI Strong Buy
- Analyst Count
- ELAB 0
- GRI 2
- Target Price
- ELAB N/A
- GRI $22.00
- AVG Volume (30 Days)
- ELAB 2.4M
- GRI 3.2M
- Earning Date
- ELAB 11-13-2025
- GRI 11-13-2025
- Dividend Yield
- ELAB N/A
- GRI N/A
- EPS Growth
- ELAB N/A
- GRI N/A
- EPS
- ELAB N/A
- GRI N/A
- Revenue
- ELAB N/A
- GRI N/A
- Revenue This Year
- ELAB N/A
- GRI N/A
- Revenue Next Year
- ELAB N/A
- GRI N/A
- P/E Ratio
- ELAB N/A
- GRI N/A
- Revenue Growth
- ELAB N/A
- GRI N/A
- 52 Week Low
- ELAB $4.29
- GRI $1.10
- 52 Week High
- ELAB $1,842.11
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- ELAB 36.26
- GRI 59.98
- Support Level
- ELAB $4.29
- GRI $1.47
- Resistance Level
- ELAB $4.89
- GRI $2.87
- Average True Range (ATR)
- ELAB 0.60
- GRI 0.20
- MACD
- ELAB -0.09
- GRI 0.06
- Stochastic Oscillator
- ELAB 12.50
- GRI 31.17
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.